TransCure bioServices adds Marc Le Bozec to its Board along with raising €2.5m funding from Financière Arbevel

– FRANCE, Archamps –  TransCure bioServices, a one-stop-shop preclinical services company dedicated to in-vivo full human immune system mouse models, today announced that it has completed a 2.5 million euros funding with Financière Arbevel.

This financing round will enable the company – healthy and profitable for the last three years – to accelerate its international sales growth as well as to expand in vivo preclinical pharmacology services offers into new product lines.

This financing was entirely subscribed by Arbevel Life Sciences Crossover I, a European private equity fund based in Paris with a cross-over approach. TransCurebioServices will use the proceeds to expand its profitable business activities in Europe and the USA and to develop additional platforms for international pharmaceutical and biotech companies.

Marc Le Bozec, Managing Director of Arbevel Life Sciences Crossover I Fund, will now join the Supervisory Board of the company and commented: “We are excited to collaborate with TransCure bioServices’ management in expediting its growth by addressing new markets and strengthening its commercial team”.

Patrick Nef, Chief Executive Officer and co-founder of TransCure bioServices, commented: “We welcome Arbevelas a new shareholder to boost our healthy and profitable international CRO business which generated significant growth over the past 3years. In addition to the ongoing full human immune system mouse models for immuno-oncology, inflammation, and infectious diseases we are excited to develop new hu-liver and 100% human monoclonal antibody services. We look forward to the contribution of Marc Le Bozec in the Supervisory Committee and to benefit from his expertise of preclinical CRO business and financial markets.”

“Arbevel’s investment underlines a steppingstone for the growth of our worldwide business,” says Stéphane Legastelois, Chairman of TransCure bioServices. “It allows TransCure bioServices to widen its range of services and to investigate new exciting areas in the field of full human antibodies.”

About TransCure bioServices SAS

TransCure bioServices SAS is a European CRO based in France offering pre-clinical in vivo pharmacology fee-for-services to international pharmaceutical, biotech, and academic customers. Uniquely designed full human immune system and hu-liver mouse models provide predictive power for drug profiling and smarter drug candidate selection for immuno-oncology, inflammation, autoimmune, infectious, liver diseases, and vaccines. If you are looking for checkpoint inhibition, CART-cell designs, 100% IgG mAb, any drug profiling involving the human immune system or hu-liver.

For more information: http://www.transcurebioservices.com

About Financière Arbevel

Founded in 1997, Financière Arbevel, an entrepreneurial investment management company, has grown significantly since its takeover by the current owners in early 2009 –the AUM progressed from EUR 25m to EUR 1.6bn as of today. The company currently employs a total of 34 staff, of which 13 are dedicated to fund management/investment research. Financière Arbevel is recognized for its expertise within the small & mid-cap asset class. We are a research-driven organization with a strong emphasis on fundamental financial and strategic analysis, close relationships with top management of listed companies and a permanent quest for new investment themes offering structural growth opportunities. The digitalization, fintech, Industry 4.0, or the ageing of the world population are some of our favorite investment themes. We ensure we 3/3 are following closely the latest developments within this universe, by participating in various conferences, trade fairs, sector-specific thematic events and by meeting regularly with the management of listed companies. Our small & mid-cap DNA is spread across various strategies under the PLUVALCA family of funds with a cross-asset approach comprising our core equity funds, thematic equity funds, fixed income, and diversified/flexible allocation funds. In 2015, the Norwegian sovereign wealth fund chose inancière Arbevel to manage its French equity mandate. In 2018, Financière Arbevel pursued its development by launching its first European private equity fund with a cross-over approach focused on the non-listed life-science universe, with the idea of accompanying a limited number of biotechnology start-ups in their development.

For more information: https://www.arbevel.com

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Comments are closed.